Introduction
The blood pressure (BP) response to changes in sodium and extracellular volume balance is heterogeneous among hypertensive patients. Patients who increase their BP with a high sodium diet or volume expansion or in whom BP is reduced following volume depletion are called salt sensitive. The rest of patients are salt resistant. [1] [2] [3] Approximately 50% of hypertensive patients are found to be salt sensitive. 4 Although the mechanisms responsible for salt sensitivity are not completely elucidated, there is evidence that they may be genetically determined. 5, 6 The relation between salt sensitivity and some genetic polymorphisms of the RAAS has been studied in the last years with contradictory results. [7] [8] [9] [10] [11] It has also been recently reported that there is no association between a polymorphism in the GNB3, implicated with enhanced G-protein activation and increased activity of the sodium-proton exchanger, and dietary salt response in normotensive men. 12 In order to further clarify the role of these polymorphisms in salt sensitivity, the aim of this study is to examine the relationship between salt sensitivity and the following polymorphisms: the angiotensinConverting enzyme (ACE) insertion/deletion (I/D), the AT1R A1166C, the CYP11B2 -344 C/T and CY11B2IC and the GNB3 C825T gene polymorphism in a group of patients with essential hypertension.
Materials and methods

Patients
A total of 102 outpatients with essential hypertension classified as stage 1 or 2, according to the VI Report of the Joint National Committee, 13 were consecutively recruited from the Hypertension and Lipids Unit of the Hospitales Universitarios Virgen del Rocío, Sevilla (Spain). Patients were under 60 years of age and the diagnosis of hypertension was established after at least three office BP measurements 4140/90 mmHg. Secondary causes of hypertension were ruled out after complete clinical, biochemical and radiological examinations. None of the patients had renal impairment, papilledema, cardiac, coronary or cerebrovascular diseases, diabetes or pregnancy. We included patients who were not previously treated or in which antihypertensive treatment was discontinued for at least 3 weeks before testing. Written informed consent was obtained from all the participants and the protocol was approved by our Hospital Ethics Committee.
Protocol
Patients were initially maintained in a 'regular' diet of 150 mEq/day of sodium for 15 days, to allow equilibrium of the systemic sodium balance and BP. Subjects then came to the Clinic after overnight fasting and without smoking, and they were assessed for salt sensitivity according to the rapid protocol of Weinberger et al.
14 Briefly, rapid volume expansion was achieved by the intravenous administration of 2l of normal (0.9%) saline over a 4 h period between 9 am and 1 pm. BP was measured three times, at 5 min intervals the last 15 min of the infusion, and the mean of these three measures was taken as the BP representative of this period. On the following day, sodium and volume depletion was accomplished by administration of a 10 mEq sodium diet and three 40 mg doses of furosemide given orally at 10 am, 2 pm and 6 pm. On the third day, patients came again to the Hospital and their BP was measured in the way previously described. We classified those individuals as salt sensitive in whom mean BP (calculated as diastolic Blood Pressure plus 1/3 of the pulse pressure) decreased X10 mmHg when comparing the measurement made at the end of the saline infusion with the one following volume depletion. The rest of patients were classified as salt resistant. Blood samples and 24 h urine collection (to confirm volume and sodium expansion and depletion) were also obtained in each period. Blood glucose, blood urea, serum creatinine and serum and urinary concentrations of electrolytes were determined by routine chemical methods. Plasma renin activity (PRA) and plasma aldosterone (PA) concentrations were assayed by radioimmunoassay.
Genomic DNA was prepared from whole blood according to standard procedures. Polymerase chain reaction (PCR) was conducted in a 50 ml volume reaction containing 20 mM Tris-HCl, pH 7.5, 100 mM KCI, 1 mM DTT, 0.1 mM EDTA, 0.5% Tween 20, 0.5% Nonidet P40, 50% glycerol, 1.5 mM MgCl 2 , 0.1 mM dNTPs, 0.4 mmol/l each primer, 2 U Taq polymerase (Roche) and 250 ng genomic DNA.
Detection of ACE I/D polymorphism
The I/D polymorphism of the ACE gene was assessed by detecting the presence (allele I, insertion) or absence (allele D, deletion) of a 287 bp in intron 16 of the ACE gene in chromosome 17 with the PCR technique and agar electrophoresis as described by Rigat et al. 15 Since the D allele is preferentially amplified in heterozygous subjects, 16 each sample found to be DD was reanalysed by a second independent PCR amplification with a primer that specifically recognises an insertion-specific sequence. 17 
Genotype determination for AT1R A1166C polymorphism
The A1166C polymorphism of the AT1 receptor was genotyped using the PCR-restriction fragment length polymorphism (RFLP) analysis. 18 
Genotyping of CYP11B2 polymorphisms
The subjects were also genotyped by PCR for two recently discovered polymorphisms in the CYP11B2 gene, chromosome 8q22 as previously described. 19 Genotype determination for GNB3 C825T polymorphism TT, CC and CT genotypes of the GNB3 gene polymorphisms were determined according to the previous reports.
20,21
Statistical analysis
The association of salt sensitivity with genotype distribution of patients was tested by w 2 test. For each genotype, we also studied the association of salt sensitivity with distribution of patients in two groups according to the condition of being or no carriers for the different alleles. One-way ANOVA was used to compare means among different groups.
Hardy-Weinberg equilibrium was tested by w 2 , values are expressed as means 7 s.d.: Po0.05 was considered to be statistically significant.
Results
Following the mentioned criteria, we found that 41 patients were salt sensitive (40.19%). General characteristics, blood chemistry, basal PRA and PA of salt-sensitive and salt-resistant patients are expressed in Table 1 . The distribution of different genotypes followed that expected by the HardyWeinberg equilibrium. Table 2 shows the distribution of ACE I/D, AT1R A1166C, GNB3 C825T and CYP11B2 -344C/T genotypes in salt-sensitive and salt-resistant patients. There were no differences between both groups of patients with regard to these genotypes. If we consider the distribution according to the condition of being or no carriers for the different alleles, the results do not change (data not shown). The decrease of BP from volume expansion to volume depletion was similar in the different genotypes (Table 3) .
In Table 4 , we report the distribution of CYP11B2 IC gene polymorphism and W vs no W allele carriers in salt-sensitive and salt-resistant patients. There were no statistically significant differences for the distribution of the three different genotypes between the groups but because the values were almost significant (w 2 ¼ 4.74, P ¼ 0.09) and the very low frequency of patients with CC genotype in the group of SS patients could be the factor determining the lack of significance, to avoid this schew we performed the w 2 for the trend with the following results: odds ratio for salt sensitivity for the group with CC genotype 1; for the CW genotype 2.46 and for the WW genotype 4.58 (w 2 ¼ 4.58, P ¼ 0.03). When comparing patients carriers of the W allele (WW plus WC genotypes) vs no carriers (CC genotype), the former group had a greater risk for salt sensitivity (Po 0.05; OR 3.02).
Discussion
The present study shows that there is no relation among salt sensitivity and ACE I/D, AT1R A1166C, CYP11B2 -344C/T, nor GNB3 C 825T polymorphisms in essential hypertensive patients. Previous studies addressing the relation between ACE I/D genotype and salt sensitivity had contradictory results: association with either II or DD genotypes or no association. [7] [8] [9] [10] [11] One possible explanation for these discrepancies is the different protocols used to assess salt sensitivity and probably the different age and ethnicity of the studied patients. We classified patients as salt sensitive or salt resistant according to the rapid protocol of Weinberger et al, 14 this method has been validated and has a good correlation with dietary techniques to assess salt sensitivity, 14, 22 and the frequency of salt sensitivity in our patients (40.19%) was the expected according to the literature. 4 In addition, we only included subjects below the age of 60 years to increase the genetic component of the studied phenotype. 23 With regard to the association between salt sensitivity and the AT1R A1166C polymorphism, our negative results are in agreement with that previously described by Giner et al 9 and Poch et al.
10
To our knowledge there are no further studies addressing this subject. The GNB3 C825T polymorphism has been studied in relation with hypertension with contradictory results. [24] [25] [26] [27] We did not find any association between this polymorphism and salt sensitivity in hypertensive patients. Similar results were found in a previous study made in normotensive men and with a dietary protocol. 12 Tamaki et al 28 and Komiya et al 29 described an association between the C-344 allele of the CYP11B2 and low renin hypertension with inappropiated elevation of aldosterone in Japanese hypertensive patients. On the contrary, a study made in Italian people found an increased frequency of the allele T and a relative excess of TT over CC homozygosity in patients with low-renin hypertension in comparison with both normal-to high-renin hypertension and normotensive controls. 30 Both studies suggested that this polymorphism might be related with salt sensitivity. However, this relation was not confirmed in a further study in Spanish population. 10 We did not find any relation between the CYP11B2 -344C/T polymorphism and salt sensitivity in agreement with the Spanish report 1010 and other study in Caucasian population. 31 In our study, there was no association between the IC of the CYP11B2 genotypes and salt sensitivity as has been previously reported. 10 This polymorphism has also been studied in relation with hypertension 32 with negative results. We did not find any difference between salt-sensitive and saltresistant patients for the distribution of the different genotypes of this polymorphism, although patients carriers of the W allele had a greater risk for salt sensitivity than no carriers. To our knowledge, this is the first report about the possible implication of this allele in salt sensitivity. Our hypothesis is that the W allele could be associated with increased activity of the enzyme determining the condition of salt sensitivity. This is plausible in view of the importance of aldosterone in sodium and water homeostasis. The similar levels of aldosterone in both groups of patients in our study are not against this possibility.
In conclusion, although we did not find any relationship among the different genotypes of the RAAS, beta-3 subunit of the G-protein and CYP11B2 and salt sensitivity in accordance with previous reports, our data show a greater risk for salt sensitivity among W allele carriers of the CYP11B2 IC polymorphism. Further studies are needed to clarify this subject. 
